From the FDA Drug Label
• INFUVITE PEDIATRIC is for administration by intravenous infusion after dilution (2.1) • Add one daily dose of Vial 1 and one daily dose of Vial 2 directly to at least 100 mL of intravenous dextrose or saline solution prior to intravenous use (2.3) • After dilution in an intravenous infusion, refrigerate resulting solution unless used immediately. Use solution within 24 hours after dilution (2.3)
The FDA drug label does not specify the administration rate for Infuvite. It provides guidance on preparation and use, but the rate of infusion is not directly stated 1.
From the Research
Infuvite (multivitamin infusion) should be administered at a rate of 10 mL per day for adults receiving parenteral nutrition, with pediatric patients receiving weight-based dosing, to minimize the risk of adverse reactions and ensure proper utilization of vitamins. The administration rate is crucial in preventing potential toxicity and adverse effects associated with vitamin infusion, as highlighted in studies such as 2, which discusses the development of a new lipid emulsion containing 13 fat- and water-soluble vitamins for injection without anaphylactoid reactions.
When administering Infuvite, it is essential to add it to the parenteral nutrition solution and administer it over the same infusion period, usually 8-24 hours, to reduce the risk of adverse reactions. The solution should be protected from light during administration, as some vitamins are photosensitive. This approach helps ensure that patients receive the necessary vitamins while minimizing potential risks.
Key considerations for administration include:
- Adult dose: 10 mL per day
- Pediatric dose: weight-based, with infants and children weighing up to 11 kg receiving 5 mL daily, and those weighing more than 11 kg receiving the adult dose
- Administration period: 8-24 hours
- Protection from light: necessary to prevent degradation of photosensitive vitamins
By following these guidelines, healthcare providers can help ensure the safe and effective administration of Infuvite, minimizing the risk of adverse reactions and promoting optimal patient outcomes, as supported by studies such as 2 and general medical knowledge.